Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jul 13:15:1-3.
doi: 10.1016/j.jdcr.2021.07.001. eCollection 2021 Sep.

Lenvatinib-induced psoriasiform eruption and palmoplantar erythema in a patient with hepatocellular carcinoma

Rachel Sally  1 , Nkemjika Ugonabo  1 , Andy Nguyen  1 , Randie H Kim  1 , Kristen Lo Sicco  1
Affiliations
Case Reports

Lenvatinib-induced psoriasiform eruption and palmoplantar erythema in a patient with hepatocellular carcinoma

Rachel Sally et al. JAAD Case Rep. .
No abstract available

Keywords: HCC, hepatocellular carcinoma; MKI, multikinase inhibitor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; drug eruption; hepatocellular carcinoma; lenvatinib; psoriasiform drug eruption; psoriasis; tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
The patient had well-demarcated, erythematous, psoriasiform plaques present on the (A) dorsal side of the hands, (B) lower extremities, and dorsal side of the feet, along with (C) cooccurring palmar-plantar dysesthesia.
Fig 2
Fig 2
A punch biopsy from the right thigh. There was regular epidermal hyperplasia with hypogranulosis beneath confluent parakeratosis, where there were collections of neutrophils. Neutrophils were seen within the epidermis. (Original magnification: ×10.)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hao Z., Wang P. Lenvatinib in management of solid tumors. Oncologist. 2020;25(2):e302–e310. - PMC - PubMed
    1. Cubero D.I.G., Abdalla B.M.Z., Schoueri J. Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors. Drugs Context. 2018;7:212516. - PMC - PubMed
    1. Ensslin C.J., Kao P.H., Wu M.Y. Psoriasiform drug eruption secondary to sorafenib: case series and review of the literature. Cutis. 2019;104(3):E11–E15. - PubMed
    1. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579–591. - PubMed
    1. Casadei Gardini A., Puzzoni M., Montagnani F. Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all phase III trials. Onco Targets Ther. 2019;12:2981–2988. - PMC - PubMed

Publication types

LinkOut - more resources